Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin
Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...
Cancer
Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure
Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...
SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial
SCG Cell Therapy Pte. Ltd, a Singapore-headquartered biotechnology company with a presence in Shanghai, has...
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...
China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug
Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced...
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
A number of healthcare companies are seeking to capitalize on the recovering market conditions by...
Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer
Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...
Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration
Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...
BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
IASO Biotherapeutics’ RD118 CAR-T Therapy Receives Clinical Trial Approval for Multiple Myeloma
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...
CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...
Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...
Amoy Diagnostics Partners with Servier to Develop Companion Diagnostic Reagent for IDH Mutations in China
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has entered into a partnership with French...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Antengene’s Xpovio Included in South Korea’s NHIS Reimbursement Drug List
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South...